Abstract
The present research investigates development and in vivo evaluation of oral diacerein formulations with quicker and complete absorption. In vivo, diacerein gets completely metabolized to its active metabolite rhein in gut and liver, which is the only analyte detected in plasma. Incomplete absorption of diacerein from the formulation leads to colonic availability of rhein, which is associated with increased laxative effect as one of the side effects of diacerein therapy. Thus solubility improved immediate release formulation (IR) and a gastroretentive formulation (GR) was designed to achieve rapid absorption preferentially through upper part of gastro-intestinal tract; thus controlling the amount of rhein reaching to colon and minimizing the associated increased laxative effect. In vitro drug release studies of the developed formulations revealed faster and complete release of diacerein from IR and GR formulations compared to commercially available diacerein capsule Art®50. Comparative bioavailability studies conducted in healthy human volunteers revealed 1.7 fold and 1.2 fold rise in AUC0-6h for IR and GR formulations respectively, compared to Art®50 capsules. A Levy plot analysis comparing association between the time of in vitro dissolution (Tvitro) of diacerein and time of in vivo absorption (Tvivo) of rhein confirmed faster release and absorption from upper part of gastrointestinal region for both the optimized formulations.
Keywords: Absorption, Area under curve, Diacerein, Levy Plot, Osteoarthritis, Plasma concentration.
Current Drug Delivery
Title:Development and Pharmacokinetic Evaluation of New Oral Formulations of Diacerein
Volume: 13 Issue: 1
Author(s): Sagar D. Mandawgade, Swati Kulkarni, Arindam Pal, Saurabh Srivastava, Bijay K. Padhi and Rajeev S. Raghuvanshi
Affiliation:
Keywords: Absorption, Area under curve, Diacerein, Levy Plot, Osteoarthritis, Plasma concentration.
Abstract: The present research investigates development and in vivo evaluation of oral diacerein formulations with quicker and complete absorption. In vivo, diacerein gets completely metabolized to its active metabolite rhein in gut and liver, which is the only analyte detected in plasma. Incomplete absorption of diacerein from the formulation leads to colonic availability of rhein, which is associated with increased laxative effect as one of the side effects of diacerein therapy. Thus solubility improved immediate release formulation (IR) and a gastroretentive formulation (GR) was designed to achieve rapid absorption preferentially through upper part of gastro-intestinal tract; thus controlling the amount of rhein reaching to colon and minimizing the associated increased laxative effect. In vitro drug release studies of the developed formulations revealed faster and complete release of diacerein from IR and GR formulations compared to commercially available diacerein capsule Art®50. Comparative bioavailability studies conducted in healthy human volunteers revealed 1.7 fold and 1.2 fold rise in AUC0-6h for IR and GR formulations respectively, compared to Art®50 capsules. A Levy plot analysis comparing association between the time of in vitro dissolution (Tvitro) of diacerein and time of in vivo absorption (Tvivo) of rhein confirmed faster release and absorption from upper part of gastrointestinal region for both the optimized formulations.
Export Options
About this article
Cite this article as:
Mandawgade D. Sagar, Kulkarni Swati, Pal Arindam, Srivastava Saurabh, Padhi K. Bijay and Raghuvanshi S. Rajeev, Development and Pharmacokinetic Evaluation of New Oral Formulations of Diacerein, Current Drug Delivery 2016; 13 (1) . https://dx.doi.org/10.2174/1567201812666150713104031
DOI https://dx.doi.org/10.2174/1567201812666150713104031 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Synthesis and Anti-Inflammatory Activity of Fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole Derivatives of Phenothiazine
Letters in Drug Design & Discovery Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies In Silico Approaches to the Design of NS5A Inhibitors
Current Topics in Medicinal Chemistry Minocycline Increases in-vitro Cortical Neuronal Cell Survival after Laser Induced Axotomy
Current Clinical Pharmacology Chondrogenesis and Developments in Our Understanding
Current Stem Cell Research & Therapy Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Gut Microbiota and Alcoholic Liver Disease
Reviews on Recent Clinical Trials Protein Tyrosine Phosphatase SHP-2 as Drug Target
Mini-Reviews in Organic Chemistry Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Tumor Organoid Model and Its Pharmacological Applications in Tumorigenesis Prevention
Current Molecular Pharmacology The Influence of Selank on the Level of Cytokines Under the Conditions of “Social” Stress
Current Reviews in Clinical and Experimental Pharmacology Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
Current Clinical Pharmacology Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design